Alexion Pharmaceuticals Stock Price - ALXN

Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Big Cap Pro
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Alexion Pharmaceuticals Inc ALXN NASDAQ Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  -1.79 -1.62% 109.00 110.79 108.345 110.67 110.79 14:40:09
Bid Price Ask Price Spread Spread % News
109.04 109.08 0.04 0.04% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
10,317 787,087 $ 109.60 $ 86,262,697 1,694,072 92.56 - 141.86
Last Trade Time Type Quantity Stock Price Currency
14:40:22 26 $ 109.0615 USD

Alexion Pharmaceuticals Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 24.12B 221.29M $ 77.60M 0.33 16.50 218.83M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Alexion Pharmaceuticals News

Loading Messages....

Latest ALXN Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ALXN Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week110.26111.04106.39108.131,373,100-1.26-1.14%
1 Month99.50111.0497.585104.601,756,5399.509.55%
3 Months113.06129.0094.59105.192,188,725-4.06-3.59%
6 Months128.68134.9894.59112.051,894,716-19.68-15.29%
1 Year123.52141.8692.56116.231,706,880-14.52-11.76%
3 Years125.76149.3492.56120.121,923,588-16.76-13.33%
5 Years195.32208.8892.56133.091,774,771-86.32-44.19%

Alexion Pharmaceuticals Description

Alexion Pharmaceuticals specializes in developing and marketing drugs for rare, life-threatening medical conditions. Its blockbuster product, Soliris, is approved for paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). Next-generation Ultomiris is approved in PNH and aHUS. Strensiq and Kanuma target other ultrarare metabolic diseases. Alexion's pipeline targets rare diseases with high unmet need in hematology, nephrology, metabolic diseases, neurology, cardiology, and other areas.

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.